Q3 EPS Estimate for Niagen Bioscience Lowered by Analyst

Niagen Bioscience, Inc. (NASDAQ:NAGE) – Investment analysts at HC Wainwright reduced their Q3 2026 earnings estimates for Niagen Bioscience in a research report issued to clients and investors on Wednesday, November 4th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.02) per share for the quarter, down from their previous forecast of $0.02. The consensus estimate for Niagen Bioscience’s current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for Niagen Bioscience’s Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at $0.05 EPS and FY2027 earnings at $0.05 EPS.

Niagen Bioscience (NASDAQ:NAGE) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.01) earnings per share for the quarter, meeting the consensus estimate of ($0.01). Niagen Bioscience had a net margin of 8.37% and a return on equity of 10.26%. The firm had revenue of $27.19 million during the quarter.

NAGE has been the subject of a number of other reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a research report on Thursday, October 15th. Canaccord Genuity Group cut their price target on Niagen Bioscience from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, October 30th. Finally, Roth Capital reiterated a “buy” rating on shares of Niagen Bioscience in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $10.00.

Niagen Bioscience Price Performance

NAGE stock opened at $2.11 on Friday. The stock has a market capitalization of $168.04 million, a PE ratio of 25.20 and a beta of 2.12. The company’s 50-day moving average is $2.79 and its 200-day moving average is $3.85. Niagen Bioscience has a 1 year low of $2.05 and a 1 year high of $7.55.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. SteelPeak Wealth LLC bought a new position in shares of Niagen Bioscience in the first quarter valued at $14,875,000. Arrowstreet Capital Limited Partnership grew its holdings in shares of Niagen Bioscience by 47.1% during the first quarter. Arrowstreet Capital Limited Partnership now owns 2,378,437 shares of the company’s stock valued at $10,489,000 after buying an additional 761,685 shares during the last quarter. Tieton Capital Management LLC acquired a new position in shares of Niagen Bioscience during the second quarter valued at about $6,407,000. Sei Investments Co. grew its holdings in shares of Niagen Bioscience by 155.6% during the first quarter. Sei Investments Co. now owns 971,574 shares of the company’s stock valued at $4,285,000 after buying an additional 591,495 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Niagen Bioscience by 45.4% during the first quarter. Renaissance Technologies LLC now owns 1,328,843 shares of the company’s stock worth $5,860,000 after acquiring an additional 414,725 shares in the last quarter. Institutional investors and hedge funds own 15.41% of the company’s stock.

Niagen Bioscience News Roundup

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: Niagen outlined a planned three-year, 5,000-participant Mass General Brigham trial and said it is targeting early 2027 commercialization of NR malate. These initiatives could support future growth, though they remain forward-looking. Article: Niagen trial and commercialization plans
• Positive Sentiment: Third-quarter net sales were $27.2 million, including $23.3 million from Tru Niagen, while direct-to-consumer sales on the company’s website grew 13% year over year. Article: Niagen Q3 2026 results
• Neutral Sentiment: Niagen’s Q3 loss of $0.01 per share matched consensus, but revenue of $27.2 million fell short of estimates. Article: Niagen Q3 results and revenue estimate
• Negative Sentiment: The company’s quarterly loss compares with earnings of $0.05 per share a year earlier, signaling weaker year-over-year profitability. Article: Niagen Q3 results
• Negative Sentiment: HC Wainwright lowered its 2027 quarterly EPS forecasts, including shifting its Q1 estimate from a profit to a $0.01 loss and reducing estimates for the other quarters. The cuts may weigh on expectations for near-term earnings. Article: Analyst estimate revisions

About Niagen Bioscience

Niagen Bioscience, Inc develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes.

Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company’s direct-to-consumer website and retail and distribution channels.